Close Menu

NEW YORK (GenomeWeb) – Curetis reported today a 38 percent drop in revenues for the full-year 2016, reflecting the receipt of nonrecurring Unyvero molecular diagnostic system revenues the year before.

For the 12-month period ended Dec. 31, 2016, Curetis' revenues fell to €1.3 million ($1.4 million) from €2.1 million in 2015. The company noted that its 2015 revenues included €900,000 in nonrecurring Unyvero sales to Asian partners for clinical trials and regulatory clearances, as well as €300,000 in pharma revenues.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.